Symbols

RNA

Atrium Therapeutics·NASDAQ

--(--)

RNA Profile

Atrium Therapeutics, Inc.

Focusing on developing a cardiac-targeted RNA delivery platform for therapies against rare inherited cardiomyopathies

Industry

Biological Technology

Established Date

09/30/2025

Listing Date

02/27/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.atriumtherapeutics.com

Security Type

Common stock

Office address

10578 Science Center Drive Suite 125 San Diego California 92121

Business

Introduction

Atrium Therapeutics, Inc., incorporated under the laws of the State of Delaware on September 30, 2025, is a direct wholly-owned subsidiary of Avidity Biosciences, Inc. The company is a biopharmaceutical company that is pioneering the delivery of RNA therapies to the heart, aiming to change the standard of care for individuals with cardiomyopathy. Leveraging a proprietary RNA delivery platform originally developed at Avidity, the company combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotides to target genetic drivers of diseases that were previously untreatable with drugs. Atrium focuses on addressing gene-driven cardiomyopathy, which affects millions of people around the world, and its development pipeline includes projects targeting specific gene drivers associated with serious heart disease. Backed by solid preclinical and positive clinical data, the company is positioned to redefine the treatment paradigm in precision cardiology.